NLRX1 and inflammatory bowel disease: DSS-induced colitis is a well-accepted model of IBD in mice, and when Nlrx1−/− mice were challenged with acute DSS treatment, increased T cell population and elevated levels of pro-inflammatory cytokines were observed in the colon, and these mice generally suffered worsened disease manifestation compared to the control group [29].